Akrivia Health

What Akrivia Health does

Akrivia Health is a UK-based precision neuroscience company, spun out of the University of Oxford and the NHS in 2019, that operates the Akrivia CRIS platform providing pharmaceutical, biotech, CRO, and academic customers with access to de-identified electronic health records from approximately 6.3-7.1 million mental health and dementia patients across 20+ NHS Trusts in England and Wales. The platform covers 19.5 billion clinical data points, 900 million clinical notes, and 5 million clinical attachments spanning 15 years of longitudinal interactions, linked to primary care and bio-sample data. Akrivia's core proprietary technology is an NLP pipeline that extracts diagnoses, symptoms, medications, and adverse events from unstructured clinical free-text notes, transforming them into structured, analyzable data fields while preserving patient privacy under NHS Research Ethics Committee approval (reference 24/SW/0101) and ISO 27001-certified storage.

The company monetizes through subscription-based data analytics and real-world evidence services to pharmaceutical and biotech customers, professional services partnerships with clinical research organizations for trial feasibility and recruitment, managed data infrastructure for NHS Trusts via the CRIS platform, and drug discovery insights for biomarker and target validation. Commercial motion is enterprise sales-driven (Book a Demo / Contact CTAs) supplemented by event-driven demand generation across BNA, RCPsych, AD/PD, BAP, SIRS, and RDF conferences. Named customers include Boehringer Ingelheim (NLP-powered cognitive impairment in schizophrenia research), Certara (Alzheimer's and mild cognitive impairment burden analysis), and multiple NHS Foundation Trusts using CRIS for service evaluation studies. The company employs 50+ people and has raised more than £30 million in Series A funding, with a flagship GlobalMinds initiative launched in February 2026 targeting 50,000+ participants combining genomics, biomarkers, deep clinical phenotyping, and patient-reported outcomes for schizophrenia, bipolar disorder, depression, Alzheimer's, and Parkinson's. AI Synapse, a generative-AI clinical development tool, is in development with a pharmaceutical partner.

Name

Akrivia Health

Legal name

CRIStal Health Limited

Website

https://akriviahealth.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Akrivia Health is a UK-based precision neuroscience company that provides pharmaceutical, biotech, CRO, and healthcare organizations with AI-curated real-world data from approximately 6.3-7.1 million NHS mental health patient records across 20+ NHS Trusts for drug discovery, clinical trial optimization, and real-world evidence generation.

Ownership category

akta.pro rank

Product category

Real-World Evidence Platform

NAICS

Web Search Portals, Libraries, Archives, and Other Information Services (5192), Web Search Portals, Libraries, Archives, and Other Information Services (519)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Patient Registries & Chronic Disease Registry Analytics (HLACAHAH)

akta.pro secondary industry

Social Determinants of Health (SDOH) & Community Resource Referral Analytics (HLACAHAG)

Keywords

• Real-world evidence data
• Clinical trial optimization
• Mental health analytics
• Electronic health records platform
• Precision neuroscience insights

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical & Biotech Data Services: Akrivia provides data analytics, cohort identification, and real-world evidence generation services to pharmaceutical and biotech companies to support drug development, clinical trials, and market access.
2. CRO Partnerships: Partnerships with Clinical Research Organisations to provide trial feasibility analysis, site selection, and patient recruitment support using real-world patient data.
3. Healthcare Organisation Data Infrastructure: Supporting NHS Trusts and healthcare organisations with CRIS platform access and data governance frameworks for research and service evaluation.
4. Drug Discovery Insights: Multi-modal data services for biomarker discovery, target validation, and early-stage research support for pharmaceutical and biotech companies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Akrivia Health provides AI-curated real-world data, clinical trial optimization, and molecular characterization services for mental health and dementia research. Its core platform aggregates de-identified electronic health records from 6.3-7.1 million NHS patients across 20+ NHS Trusts, using proprietary NLP models to extract clinically relevant insights from unstructured clinical notes for pharmaceutical, biotech, CRO, and healthcare organization partners.

Product overview

Akrivia Health operates as a precision neuroscience company offering a platform-based portfolio centered on the Akrivia CRIS research platform, which provides access to de-identified mental health EHR data from 7.1 million NHS patients across 20+ NHS Trusts. The platform is complemented by three commercial solution modules: Clinical & Commercial Solutions (supporting pharmaceutical R&D, regulatory, HEOR, and pharmacovigilance), Drug Discovery Insights (enabling biomarker discovery and early-phase asset support), and Rare & Orphan Disease Programmes (for underserved CNS populations). The flagship GlobalMinds initiative combines genomics and AI for precision neuroscience research, while AI Synapse (in development) aims to support clinical development through AI-curated data. The RLDA platform provides live cohort exploration for record-level data access.

Differentiator

Problem solved

Functional benefit

Products and services

• Akrivia CRIS (Clinical Record Interactive Search) A research platform that allows healthcare organisations and NHS Trusts to securely search and analyse de-identified electronic health records across 20+ NHS Trusts in England and Wales, supporting health research using anonymised patient information.
• Clinical & Commercial Solutions A solution module that partners with pharmaceutical companies to support research & development, regulatory approval, HEOR & market access, and pharmacovigilance & medical affairs through real-world data access and patient cohort characterization.
• Drug Discovery Insights Uses longitudinal, multi-modal datasets to uncover novel biomarkers, validate mechanisms of action, and de-risk early-stage CNS drug investments through prospective cohort building and multimodal data integration.
• Rare & Orphan Disease Programmes Enables access to curated data in underserved rare CNS and neurodegenerative disorder populations for precision medicine, supporting patient detection via NLP and EHR, disease understanding, treatment pathway mapping, trial design, and regulatory submission.
• GlobalMinds A 50,000+ participant precision neuroscience initiative combining genomic data, biomarkers, deep clinical phenotyping, and patient-reported outcomes to drive breakthroughs in diagnostics, treatments, and care for depression, schizophrenia, bipolar disorder, Alzheimer's, and Parkinson's.
• Real Live Data Access (RLDA) Platform Provides live cohort exploration capabilities allowing researchers to access record-level anonymised data extracted via NLP from EHR clinical notes in tabular form, including diagnosis, medication, signs and symptoms.

Quantifiable outcome

• 6.3-7.1 million unique patient records accessible for research
• +2 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• Boehringer IngelheimcoreStrategic or Co-development Partner · 1 June 2026Global pharmaceutical company partnered on NLP-powered research analyzing cognitively impaired schizophrenia patients and real-world data on cognitive impairment in schizophrenia, with published case studies.
• Cardiff UniversitycoreStrategic or Co-development Partner · 17 February 2026Cardiff University is a key academic partner in the GlobalMinds study led by Akrivia Health, contributing to the three-year research initiative analyzing DNA samples combined with health records to identify associations between genes, background, biology, and mental health conditions.
• NHS England (DigiTrials)coreStrategic or Co-development Partner · 17 February 2026NHS England's DigiTrials service is used to identify and invite potential participants for the GlobalMinds study, enabling large-scale, data-driven recruitment using national health data to reach individuals who may be eligible for research.
• SMARTbiomed (University of Oxford & Denmark collaboration)supportingStrategic or Co-development Partner · 1 June 2025Two-day hands-on workshop hosted by Akrivia Health with SMARTbiomed collaboration between University of Oxford and Denmark, walking researchers through how to use longitudinal psychiatric EHR data effectively.
• Rethink Mental IllnesssupportingGTM or Marketing Partner · 1 January 2025Partnership with Rethink Mental Illness for engagement activity associated with the GlobalMinds study, focused on using real-world data from NHS records to support research into conditions such as schizophrenia, dementia, and other serious mental illnesses.
• CertaracoreStrategic or Co-development PartnerGlobal biopharma company using Akrivia's RLDA platform to independently analyze data on Alzheimer's and mild cognitive impairment burden in the UK, demonstrating commercial partnership for real-world evidence generation.
• University of Oxford (Oxford University Innovation)coreStrategic or Co-development PartnerAkrivia is a spin-out from the University of Oxford. Steve Silvey, Deputy Head of Life Sciences at Oxford University Innovation, serves as Board Member representing the university's interests and leading digital health and medical technologies.
• Tempus AIsupportingStrategic or Co-development PartnerHailey Lefkofsky, Board Member at Akrivia Health, previously helped establish Tempus AI's core data infrastructure and led development of early analytic tools, with Tempus expanding into neuropsychiatry for personalized treatment decisions.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Tempus AI: AI-driven precision medicine data platform offering real-world clinical and molecular data to pharma and providers. Directly comparable: Tempus is expanding into neuropsychiatry and shares board-level DNA with Akrivia via Hailey Lefkofsky, competing for the same pharma R&D wallet.
• Flatiron Health: EHR-derived real-world oncology data platform acquired by Roche; sells curated clinical datasets and analytics to life sciences. Comparable to Akrivia as a direct EHR-to-RWE pipeline model, though Akrivia is specialised in CNS/mental health rather than oncology.
• TriNetX: Federated global health-data network providing real-world patient data for clinical trial feasibility, cohort identification and protocol optimisation to pharma and CROs. Closely mirrors Akrivia's CRIS platform business model and CRO partnership motion.

Broad incumbents

• IQVIA: Largest global real-world evidence and clinical research services provider, offering broad RWE, HEOR and trial-design analytics to pharma. Overlaps with Akrivia across RWE and trial feasibility but at vastly greater scale and across all therapeutic areas.
• Foundation Medicine (Roche): Genomic profiling and clinico-genomic data business for oncology R&D within Roche. Comparable as a pharma-facing molecular data + clinical annotation platform, though focused on oncology rather than CNS/mental health.

Emerging players

• Owkin: AI/ML platform partnering with academic medical centres and pharma to deploy federated learning on real-world clinical and molecular data for drug discovery. Adjacent to Akrivia in using EHR/multi-modal data to accelerate pharma R&D, with overlapping pharma customer base.
• Verily (Alphabet): Alphabet-owned precision health company building data platforms (e.g. Baseline, Viewpoint) for clinical research and real-world evidence. Competes for the same large-pharma RWE budgets as Akrivia, particularly in chronic disease and CNS-adjacent cohorts.
• Mendel: AI platform that structures EHR and clinical-trial data to support pharma real-world evidence, cohort building and medical affairs. Similar NLP-on-EHR architecture to Akrivia's pipeline, but applied across general medical records rather than mental health.
• Health Catalyst: Healthcare data and analytics platform aggregating clinical and operational data for providers, payers and life sciences. Comparable in selling curated, governance-ready clinical datasets to pharma and provider systems.
• Datavant: Health data connectivity and tokenisation platform enabling privacy-preserving linkage of EHR, claims and registry data for research. Adjacent enabling-layer peer whose de-identification and linkage technology underpins many RWE workflows similar to Akrivia's.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/akriviahealth
• Facebookfacebook.com/profile.php?id=100088816032652
• LinkedInlinkedin.com/company/akrivia-health
• Instagraminstagram.com/akrivia.health

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akrivia Health